Papers by Daniel Breadner
Journal of clinical oncology, Jun 1, 2024
Bookmarks Related papers MentionsView impact
Annals of hepato-biliary-pancreatic surgery/Annals of Hepato-Biliary-Pancreatic surgery, Feb 1, 2024
Bookmarks Related papers MentionsView impact
Journal of gastrointestinal oncology, Sep 30, 2023
Bookmarks Related papers MentionsView impact
Journal of Gynecologic Oncology, Dec 31, 2023
Bookmarks Related papers MentionsView impact
Journal of Clinical Oncology, May 20, 2018
Bookmarks Related papers MentionsView impact
Therapeutic Advances in Medical Oncology, 2023
The combined use of stereotactic ablative radiotherapy (SABR) and immune checkpoint inhibitors (I... more The combined use of stereotactic ablative radiotherapy (SABR) and immune checkpoint inhibitors (ICIs) is an emerging treatment paradigm for oligometastatic non-small-cell lung cancer (NSCLC). Recent phase I and II trial data suggest that SABR to multiple metastases in addition to ICI use is safe and effective with promising progression-free survival and overall survival signals. There is great interest in capitalizing on combined immunomodulation from these two modalities for the treatment of oligometastatic NSCLC. Ongoing trials seek to validate the safety, efficacy, and preferred sequencing of SABR and ICI. This narrative review of the role of SABR when combined with ICI in oligometastatic NSCLC discusses the rationale for this bimodality treatment, summarizes recent clinical trial evidence, and proposes key principles of management based on the available evidence.
Bookmarks Related papers MentionsView impact
Research Square (Research Square), May 16, 2022
Bookmarks Related papers MentionsView impact
International Journal of Radiation Oncology Biology Physics, Apr 1, 2018
Bookmarks Related papers MentionsView impact
Journal of Clinical Oncology, Jun 1, 2023
Bookmarks Related papers MentionsView impact
Journal of medical imaging, Feb 21, 2023
Bookmarks Related papers MentionsView impact
Journal of Gastrointestinal Oncology
Bookmarks Related papers MentionsView impact
Metastasis is the cause of 90% of cancer deaths. The detection of neoplasms before they metastasi... more Metastasis is the cause of 90% of cancer deaths. The detection of neoplasms before they metastasize using non-invasive molecular imaging approaches can have a significant impact on patient survival. For many years it has been known that αvβ3 integrin, which is over-expressed on angiogenic endothelium and many tumours, associates with the extracellular matrix through an RGD tripeptide motif. RGD-mediated targeting has been utilized for a wide variety of peptide and nanoparticle molecular imaging agents that are in various stages of development and in clinical trials. As RGD peptide decreases cell adhesion, concerns regarding its utilization as a molecular imaging agent have been raised (Kiessling et. al., 2009 Radiology). RGD peptides exert an anti-angiogenic effect through their inhibition of αvβ3 integrin, raising the concern given recent studies (Ebos et. al., 2009 Cancer Cell v15; Paez-Ribes et. al., 2009 Cancer Cell v15) that this anti-angiogenic activity may result in increased tumour invasion and metastasis. We sought, therefore, to discover novel αvβ3 integrin-targeted peptides that do not contain RGD for the development of new molecular imaging agents. Using a recently developed “beads on a bead” approach, we screened a linear octapeptide one bead one compound library using purified αvβ3 integrin. Over one hundred peptides were isolated and sequenced “on bead” using a novel MALDI-TOF/MS technique and a number of non-RGD containing peptides were identified. Two of these peptides had a higher binding affinity for purified αvβ3 integrin than the linear RGD peptide (LCE62, KD = 4.7 nM and LCE64, KD = 16.3 nM) as determined by surface plasmon resonance. In contrast to peptides containing RGD, these peptides did not impact the morphology and adhesion of αvβ3 integrin-expressing MDA-435 cells, nor did they inhibit angiogenesis. The uptake of both fluorescein-labeled LCE62 and LCE64 by αvβ3 integrin-expressing breast cancer cells were significantly higher compared with a control AGD peptide. We have also demonstrated that this uptake was effectively blocked by an excess of free unlabeled peptide. These novel αvβ3 integrin-binding peptides could provide a basis for a new and potentially safer generation of molecular imaging agents for the early diagnosis of cancers. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1763. doi:10.1158/1538-7445.AM2011-1763
Bookmarks Related papers MentionsView impact
Bioorganic & Medicinal Chemistry, Feb 1, 2010
Novel Glucagon-Like Peptide-1 (GLP-1) derivatives containing the metal chelator DOTA (1,4,7,10-te... more Novel Glucagon-Like Peptide-1 (GLP-1) derivatives containing the metal chelator DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) and naturally occurring Indium (113/115In) were prepared using solid-phase Fmoc methods. All synthesized peptides contained d-Ala-8, a modification known to improve resistance towards degradation by dipeptidyl peptidase-IV. The effect of increased distance between DOTA and the peptide chain was investigated using an (aminoethyl) ethoxy acetyl linker, in order
Bookmarks Related papers MentionsView impact
Dalton Transactions, 2012
Bookmarks Related papers MentionsView impact
The Journal of Physical Chemistry C, 2007
Bookmarks Related papers MentionsView impact
Nano Letters, Oct 29, 2012
Bookmarks Related papers MentionsView impact
Case Reports in Oncology
This case report outlines a 70-year-old female patient who presented with a concurrent mixed auto... more This case report outlines a 70-year-old female patient who presented with a concurrent mixed autoimmune hemolytic anemia (AIHA) and a gastric adenocarcinoma. Her treatment course of these two diseases is summarized, which included supportive care, neoadjuvant chemotherapy for her gastric adenocarcinoma, steroids, rituximab, and surgical resection of the tumor. This approach ultimately led to the stabilization of her AIHA and primary cure for her solid malignancy. We briefly review both AIHA and gastric adenocarcinoma as clinical entities, propose working causes of hemolytic anemia including gastric adenocarcinoma, and outline a successful treatment pathway for these two concurrent conditions.
Bookmarks Related papers MentionsView impact
Cellular oncology, Dec 17, 2019
Bookmarks Related papers MentionsView impact
Pharmacogenomics research and personalized medicine, 2022
Bookmarks Related papers MentionsView impact
Current Oncology, Oct 9, 2021
Bookmarks Related papers MentionsView impact
Uploads
Papers by Daniel Breadner